[go: up one dir, main page]

WO2006053955A3 - Method and kit for detecting a risk of essential arterial hypertension - Google Patents

Method and kit for detecting a risk of essential arterial hypertension Download PDF

Info

Publication number
WO2006053955A3
WO2006053955A3 PCT/FI2005/050429 FI2005050429W WO2006053955A3 WO 2006053955 A3 WO2006053955 A3 WO 2006053955A3 FI 2005050429 W FI2005050429 W FI 2005050429W WO 2006053955 A3 WO2006053955 A3 WO 2006053955A3
Authority
WO
WIPO (PCT)
Prior art keywords
risk
kit
detecting
arterial hypertension
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FI2005/050429
Other languages
French (fr)
Other versions
WO2006053955A2 (en
Inventor
Jukka T Salonen
Juha-Matti Aalto
Ricardo Fuentes
Outi Kontkanen
Mia Pirskanen
Pekka Uimari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jurilab Ltd Oy
Original Assignee
Jurilab Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041490A external-priority patent/FI20041490A0/en
Application filed by Jurilab Ltd Oy filed Critical Jurilab Ltd Oy
Priority to EP05813226A priority Critical patent/EP1824996A2/en
Priority to JP2007542026A priority patent/JP2008521392A/en
Priority to AU2005305765A priority patent/AU2005305765A1/en
Priority to CA002587979A priority patent/CA2587979A1/en
Publication of WO2006053955A2 publication Critical patent/WO2006053955A2/en
Publication of WO2006053955A3 publication Critical patent/WO2006053955A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Genes, SNP markers and haplotypes of susceptibility or predisposition to hypertension (HT) are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for HT using polymorphisms in the HT risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of HT. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of HT.
PCT/FI2005/050429 2004-11-19 2005-11-21 Method and kit for detecting a risk of essential arterial hypertension Ceased WO2006053955A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05813226A EP1824996A2 (en) 2004-11-19 2005-11-21 Method and kit for detecting a risk of essential arterial hypertension
JP2007542026A JP2008521392A (en) 2004-11-19 2005-11-21 Method and kit for measuring the risk of developing essential arterial hypertension
AU2005305765A AU2005305765A1 (en) 2004-11-19 2005-11-21 Method and kit for detecting a risk of essential arterial hypertension
CA002587979A CA2587979A1 (en) 2004-11-19 2005-11-21 Method and kit for detecting a risk of essential arterial hypertension

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FI20041490 2004-11-19
FI20041490A FI20041490A0 (en) 2004-11-19 2004-11-19 Method and test package for detecting the risk of substantially elevated blood pressure
US11/245,248 US20060110751A1 (en) 2004-11-19 2005-10-07 Method and kit for detecting a risk of essential arterial hypertension
US11/245,248 2005-10-07

Publications (2)

Publication Number Publication Date
WO2006053955A2 WO2006053955A2 (en) 2006-05-26
WO2006053955A3 true WO2006053955A3 (en) 2006-08-31

Family

ID=36407505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2005/050429 Ceased WO2006053955A2 (en) 2004-11-19 2005-11-21 Method and kit for detecting a risk of essential arterial hypertension

Country Status (4)

Country Link
EP (1) EP1824996A2 (en)
AU (1) AU2005305765A1 (en)
CA (1) CA2587979A1 (en)
WO (1) WO2006053955A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003826A1 (en) * 2006-07-07 2008-01-10 Oy Jurilab Ltd Novel genes and markers in essential arterial hypertension
KR100818276B1 (en) * 2006-09-27 2008-03-31 삼성전자주식회사 Primer sets, probe sets, methods and kits for predicting alcohol degradability and hangover occurrence
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
TWI363309B (en) * 2006-11-30 2012-05-01 Navigenics Inc Genetic analysis systems, methods and on-line portal
RU2322183C1 (en) * 2006-12-11 2008-04-20 Государственное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей Федерального агентства по здравоохранению и социальному развитию" Method for evaluating arterial hypertension treatment effectiveness in 22-35 years old patients
FI20096188A0 (en) * 2009-11-16 2009-11-16 Mas Metabolic Analytical Servi Nutrigenetic biomarkers for obesity and type 2 diabetes
RU2592249C1 (en) * 2015-05-29 2016-07-20 Олег Геннадьевич Архипов Method for prediction of physical rehabilitation of patients with arterial hypertension

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048245A2 (en) * 1999-12-27 2001-07-05 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2002060942A2 (en) * 2001-01-31 2002-08-08 Incyte Genomics, Inc. Protein modification and maintenance molecules
WO2003083046A2 (en) * 2002-03-08 2003-10-09 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2004009842A2 (en) * 2002-07-24 2004-01-29 Rheoscience A/S Methods for identifying genes related to malfunctions of the central nervous system
WO2004063340A2 (en) * 2003-01-13 2004-07-29 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048245A2 (en) * 1999-12-27 2001-07-05 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2002060942A2 (en) * 2001-01-31 2002-08-08 Incyte Genomics, Inc. Protein modification and maintenance molecules
WO2003083046A2 (en) * 2002-03-08 2003-10-09 Curagen Corporation Novel proteins and nucleic acids encoding same
WO2004009842A2 (en) * 2002-07-24 2004-01-29 Rheoscience A/S Methods for identifying genes related to malfunctions of the central nervous system
WO2004063340A2 (en) * 2003-01-13 2004-07-29 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
ASKEW Y.S. ET AL.: "SERPINB12 Is a Novel Member of the Human ov-serpin Family Thas Is WIdely Expressed and Inhibits Trypsin-like Serine Proteinases", vol. 276, no. 52, 28 December 2001 (2001-12-28), pages 49320 - 49330, XP002956377 *
CHO H. ET AL.: "The aorta and heart differentially express RGS (regulators of G-protein signalling) proteins that selectively regulate sphingosine 1-phosphate, angiotensin II and endothelin-1 signalling", BIOCHEM. J., vol. 371, 2003, pages 973 - 980, XP002999110 *
COTE F. ET AL.: "Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function", PNAS, vol. 100, no. 23, 11 November 2003 (2003-11-11), pages 13525 - 13530, XP002999104 *
DATABASE EMBASE [online] MILLER-KASPRZAK E. ET AL.: "The role of platelet-derived growth factor A (PDGF-A) in hypertension and renal diseases. Part 1: Structure and regulation of the PDGF-A gene expression and its role in hypertension", XP002999105, Database accession no. (EMB-2004230926) *
DOGGRELL S.A.: "Is RGS-2 a new drug development target in cardiovascular disease?", EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 8, no. 4, 2004, pages 355 - 358, XP002999111 *
HOPKINS P.N. ET AL.: "Genetics of hypertension", GENETICS IN MEDICINE, vol. 5, no. 6, November 2003 (2003-11-01) - December 2003 (2003-12-01), pages 413 - 429, XP008066769 *
JARROT B. ET AL.: "Serotonin levels in vascular tissue and the effects of a serotonin synthesis inhibitor on blood pressure in hypertensive rats", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, no. SUPPL. 2, 1995, pages 201 - 205, XP002999103 *
KAUHANEN J. ET AL.: "G-protein Beta3 subunit C825T polymorphism: no association with risk for hypertension and obesity", JOURNAL OF HYPERTENSION, vol. 19, no. 12, 2001, pages 2149 - 2155, XP008066765 *
KOIVUKOSKI L. ET AL.: "Meta-analysis of genome-wide scans for hypertension and blood pressure in Caucasians shows evidence of susceptibility regions on chromosomes 2 and 3", HUMAN MOLECULAR GENETICS, vol. 13, no. 19, 2004, pages 2325 - 2332, XP002999107 *
KRISTJANSSON K. ET AL.: "Linkage of Essential Hypertension to Chromosome 18q", HYPERTENSION, vol. 39, 2002, pages 1044 - 1049, XP002999112 *
LAIVUORI H. ET AL.: "Susceptibility Loci for Preeclampsia on Chromosomes 2p25 and 9p13 in Finnish Families", AM. J. HUM. GENET., vol. 72, no. 168, 2003, pages 168 - 177, XP002999108 *
LOOS R.J.F. ET AL.: "Genome-Wide Linkage Scan for the Metabolic Syndrome in the HERITAGE Family Study", THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 88, no. 12, 2003, pages 5935 - 5943, XP002999109 *
MALNIC B. ET AL.: "The human olfactory receptor gene family", PNAS, vol. 101, no. 8, 24 February 2004 (2004-02-24), pages 2584 - 2589, XP002999106 *
MORRIS B.J. ET AL.: "Essential Hypertension: Genes and Dreams", CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol. 41, no. 7, 2003, pages 834 - 844, XP008066771 *
POLSKI MERKURIUSZ LEKARSKI, vol. 16, no. 94, 2004, pages 398 - 401 *
RICE T. ET AL.: "Genomewide Linkage Scan of Resting Blood Pressure HERITAGE Family Study", HYPERTENSION, vol. 39, 2002, pages 1037 - 1043, XP002302275 *
TOIVONEN H.T.T. ET AL.: "Data Mining Applied to Linkage Disequilibrium Mapping", AM. J. HUM. GENET., vol. 67, 2000, pages 133 - 145, XP000995225 *
VEENSTRA-VANDERWEELE J. ET AL.: "Pharmacogenetics and the serotonin system: initial studies and future directions", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 410, 2000, pages 165 - 181, XP002255279 *

Also Published As

Publication number Publication date
EP1824996A2 (en) 2007-08-29
AU2005305765A1 (en) 2006-05-26
CA2587979A1 (en) 2006-05-26
WO2006053955A2 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
FI20050011A7 (en) Method and test kit for detecting the risk of type 2 diabetes mellitus
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2009059317A3 (en) Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2007045197A3 (en) Expression profiles for predicting septic conditions
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
WO2007088537A3 (en) Methods and kits for early detection of cancer or predisposition thereto
Freudenberger et al. Genetics of age-related white matter lesions from linkage to genome wide association studies
WO2005054503A3 (en) Biomarkers for graft rejection
WO2008137121A3 (en) Methods for detecting an increased risk for coronary heart disease
WO2010103292A3 (en) A genotyping tool for improving the prognostic and clinical management of ms patients
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2006053955A3 (en) Method and kit for detecting a risk of essential arterial hypertension
WO2007067476A3 (en) Methods for predicting treatment response based on the expression profiles of protein and transcription biomakers
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
EP3075865A3 (en) Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2006119775A3 (en) Method for diagnosis and treatment, of a mental disease
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
WO2007002300A3 (en) Non-in situ hybridization method for detecting chromosomal abnormalities
WO2007120975A8 (en) Variants in complement regulatory genes predict age-related macular degeneration
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2008018789A3 (en) Methods and means for diagnosing and treatment of osteoarthritis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2007542026

Country of ref document: JP

Ref document number: 2587979

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005305765

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005813226

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005305765

Country of ref document: AU

Date of ref document: 20051121

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005305765

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580046895.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005813226

Country of ref document: EP